Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
about
Local treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.Opportunistic intraocular infections in AIDSThe use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS.Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.Treatment of herpesvirus infections in HIV-infected individuals.Age-related differences in pharmacokinetics of phosphonoformate in cats.Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitisOpportunistic infections in HIV-infected patients.Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.Antiviral therapy: current concepts and practicesAntineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis.High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDSCurrent and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells.Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group."The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.Treatment of human immunodeficiency virus infection and its associated complications in children.In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.Neurologic sequelae associated with foscarnet therapy.Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.Cytomegalovirus retinitis: diagnosis and treatment.Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study.Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
P2860
Q33569565-B3F363FB-0FD6-4982-9191-864AF6769A5FQ34163746-FD9047CB-EFE9-4143-A32B-B6FEC7E82C53Q34711049-2F5F2489-7DD1-46E8-B6B4-36BD12348B9BQ35118174-4396860C-ABCC-4887-87DA-22BF3D353ABBQ35231928-C5751EEE-9E33-407D-896A-FAFC510B41E4Q35254452-BEA71699-059F-423A-928E-AF43F6266008Q35333643-A453214E-D112-4DE3-AD59-C8F0B93FE934Q35821073-16A7C30A-07C6-4679-A7A9-BCF1E9788450Q35893214-63A6BB9F-E346-4E5F-8220-9A3E29311907Q35894405-CF43E1E6-EDE6-4F90-B0C6-54BC74F5E251Q35896783-4C8E3D92-4A32-49F4-ABA8-549B1DB63A4AQ36070394-DFC11E4D-A9D2-4947-BE9B-0EAA91BE1B74Q36929871-3825B287-04C5-47A6-9688-E21042210B92Q37304750-70F16FF3-66DC-41E3-90C2-C74B0279161AQ37308378-D32C15EB-F7ED-4309-BA24-CE9D5C136FABQ37951633-28604427-2EE0-46E2-8CB0-0D0B8226CB6BQ39474633-AE9E5A0C-BD59-40E0-8EC7-DC3EA4FF745EQ39781466-C38EFB93-721B-49B6-9988-D4725BD4165EQ40087885-8707F4D9-3185-45A1-8AF1-079153D51344Q40284739-821C20C7-3832-4B3B-9799-333C121EB87CQ40720231-82433C0D-505B-412B-92CB-7352A119E486Q40727613-ABC05A2C-4529-4C55-89F9-E7BA6C2AD5EEQ40794956-BF18D736-11C1-4343-A105-8FC32FBCB7B7Q40853845-D0B87B44-D422-489E-91AD-10A87FC8DA0BQ42280002-9FA94BBE-3218-4417-BF40-399E01536F8CQ42282299-03AB0DB7-6A8C-47A7-B399-4E2711120CB0Q42288776-352D7906-83C5-447D-8B6F-1804E8D34B2CQ44031712-5F2CFFDC-36EF-4ECE-B401-88B10358DE8FQ45778365-38DAB7D8-FADC-4DDF-A867-9F80F3DC01FAQ46393134-01A9B0DE-73B5-4A05-B14E-74C07AC6F33D
P2860
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@ast
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@en
type
label
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@ast
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@en
prefLabel
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@ast
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@en
P2093
P2860
P356
P1476
Foscarnet treatment of cytomeg ...... red immunodeficiency syndrome.
@en
P2093
J J O'Donnell
M A Jacobson
P2860
P304
P356
10.1128/AAC.33.5.736
P407
P577
1989-05-01T00:00:00Z